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Abstract The study of stem-cell biology has been a
flourishing research area because of its multi-differentia-
tion potential. The emergence of induced pluripotent stem
cells (iPSCs) open up the possibility of addressing
obstructs, such as the limited cell source, inherent com-
plexity of the human brain, and ethical constrains. Though
still at its infancy phase, reprogramming of somatic cells
has been demonstrating the ability to enhance in vitro study
of neurodegenerative diseases and potential treatment.
However, iPSCs would not thoroughly translate to the
clinic before limitations are addressed. In this review, by
summarizing the recent development of iPSC-based mod-
els, we will discuss the feasibility of iPSC technology on
relevant diseases depth and illustrate how this new tool
applies to drug screening and celluar therapy.
Keywords Induced pluripotent stem cells  IPSCs 
Neurodegenerative disease  Disease modeling  Drug
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Introduction
Neurodegenerative diseases occur as a result of neurode-
generative processes, including chronic and progressive
loss of structure or function of neurons. Compared with
other organs, recent progress in the molecular basis of
neurodegenerative disorders has evolved slowly. This
mainly due to brain tissue samples were rarely available for
obtaining and often demonstrated the final phase of the
diseases. These limitations impede our progress for better
understanding of disease onset and mechanisms [1].
Although genetically engineered animal models have
achieved promising advances, these systems are still
inadequate and do not faithfully mirror the disease mech-
anism due to species differences and genetic backgrounds.
Possessing the developmental potential to form trophoblast
and differentiate into three embryonic germ layers, human
embryonic stem cells (hESCs) could be a new paradigm
[2]. However, the success rate of hESC establishment is
extremely low, combining with lacking of oocyte donors
and ethical issues further restricted the extensive applica-
tion. The recent method of obtaining induced pluripotent
stem cells (iPSCs) from somatic cells offer unprecedented
and exciting opportunities to solve multiple drawbacks of
various models mentioned above. The aim of this review is
to assess the recent literatures and key findings on mod-
eling neurodegenerative disease using iPSCs. The potential
of iPSCs as an ideal platform for drug screening and cell
therapy are presented. Besides, limitations and challenges
in iPSC modeling will also be discussed.
The developmental process of iPSC technology
Yamanaka first illustrated how cell fates rewound to a pre-
embryonic state using retroviruses and lentiviruses by the
ectopic co-expression of transcription factors [3, 4]. That
discovery won him the Nobel Prize for Medicine in 2012.
These iPS cells subsequently converted to specific cells of
interest, such as neurons and glia that are relevant for
different neurodegenerative diseases. However, it is also
time-consuming, expensive. Moreover, this new approach
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possesses the possibility of oncogene reactivation when the
cocktail of reprogramming factors contained proto onco-
gene c-MYC and the risk of insertional mutations. To
reduce the potential adverse effects and to emphasize the
need to safety, hiPSCs have been established by excluding
c-MYC of four conventional reprogramming factors [5, 6].
Several groups took advantages of adenoviral and plasmid
for non-integrating which avoid tumor formation, however,
these manners are very labor intensive and the efficiency in
general is extremely low [7, 8]. Sendai virus, protein,
modified mRNA, and Micro-RNA have been used to
generate iPSCs with no genomic integration [9–13]. The
disadvantages of each vector type are still apparent. For
example, the problems of purging cells of replicating virus
and sequence-sensitive RNA replicase when applying
Sendai virus can not be ignored [13]. Multiple rounds of
transfection using modified mRNA vector were needed to
achieve controllable and high-efficiency goal [12].
Recently, researchers have obtained mouse iPSCs from
somatic cells using a combination of small-molecule
compounds because they are cost-effective, easily synthe-
sized, and nonimmunogenic [14]. Important progresses of
iPSC-based scientific exploration have already been made
on neurological diseases, haematological diseases, cardiac
diseases, liver related diseases, etc. Here, we focus on
current-established iPSCs models on neurodegenerative
disorders (summarized in Table 1).
Parkinson’s disease
Parkinson’s disease (PD) is the most common form of a
group of progressive neurodegenerative movement disor-
ders, and the prevalence is about 100–300 per 100,000
[15]. Initial PD-iPS cells were generated to reveal aspects
of the abnormalities of PD, but no relevant phenotype was
evident in the study [16]. Later, iPSC lines from a patient
harboring a mutation in LRRK2 gene were found partially
consistent with early PD phenotype of enhanced suscepti-
bility to oxidative stress (OS) [17]. In LRRK2 G2019S
iPSC-derived dopaminergic (DA) neurons, morphological
Table 1 Summary of reported iPSC-based disease models for neurodegenerative diseases
Disease Associated
gene




PD LRRK2 Fibroblasts and
epidermal
keratinocytes
Dopaminergic neurons Yes Mutant allele correction [17–19]
PINK1 Fibroblasts Dopaminergic neurons Yes PINK1 overexpression [20]
PARK2 Fibroblasts Dopaminergic neurons Yes Lentiviral expression of Parkin [21, 22]
SNCA Fibroblasts Dopaminergic neurons Yes Mutant allele correction [23, 24]
GBA1 Fibroblasts Dopaminergic neurons Yes Mutant allele correction [25]
AD PS1 and
PS2
Fibroblasts Neurons Yes c-Secretase inhibitors and
modulators
[28, 29]
APP Fibroblasts Neurons Yes b-Secretase inhibitors [30]
Sporadic Fibroblasts Neurons and astrocytes Yes Docosahexaenoic acid [31]
HD HTT Fibroblasts Neural stem cells, neuronal
precursors striatal neurons, and
astrocytes
Yes Proteasome inhibitors and
normal repeat substitution
[34–39]
ALS SOD1 Fibroblasts Motor neurons Yes Conditional expression of
neurofilament-L
[43, 44]
TDP-43 Fibroblasts Motor neurons and astrocytes Yes Anacardic acid [45, 46,
48]
VAPB Fibroblasts Motor neurons Yes No [47]
SMA SMN1 GM09677
fibroblasts




FRDA FXN Fibroblasts Peripheral sensory neurons and
neural crest progenitors
Yes No [60, 61]
MJD ATXN3 Fibroblasts Neurons Yes Calpain inhibition [63]
FD IKBKAP Fibroblasts Neural crest precursors and
neurons
Yes Kinetin, glucosaminic acid,
SKF-86466, phenindione, etc.
[65–67]
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alterations were observed when compared to control lines,
with neurons showing decreased neurite length and reduced
numbers of neuritis. This study also observed accumulation
of autophagosomes and reduction of autophagic flux [18].
Recently, the phenotypes in two patient-derived iPSC lines
with LRRK2 G2019S mutation were rescued by specifically
correcting the corresponding mutant allele. Moreover,
certain experiment highlighted an elevated level of a-
synuclein and MAPT expression in counterpart lines while
not in the LRRK2 genetically corrected lines [19]. Muta-
tions in either PINK1 or PARK2 cause recessive forms of
inherited PD characterized by impaired mitophagy because
PINK1 and Parkin proteins function together. A study,
including three patients with missense (c.509T[G;
p.V170G) in mitochondrial protein PINK1, reported that
the PINK1 mutant phenotype could be reversed after
overexpression of wild-type PINK1 [20]. In studies
examining iPSC cells from patients with PARK2 mutations,
iPSC-derived neurons demonstrated functional and mor-
phological abnormalities of mitochondria along with
increased oxidative stress, rather than iPSCs or fibroblasts
[21]. Similar to Imaizumi and colleagues, Jiang et al. [22]
demonstrated altered features in mutant DA neurons,
including enhanced sensibility to OS and monoamine
oxidases activity, increased spontaneous DA release, and
decreased DA uptake. These phenotypes were reversed
through lentiviral expression of Parkin. Human iPSC-
derived lines with mutations in SNCA expressed double the
amount of a-synuclein when differentiated into DA neu-
rons, while not seen in the original fibroblasts [23]. By use
of zinc finger nuclease-mediated genome editing technol-
ogy, researchers corrected the underlying point mutations
(A53T) in SNCA-PD-iPSC. However, the phenotypes of
iPSC-derived neurons in this work were not assessed [24].
A more recent study applied iPSCs possessing GBA1
mutations to the modeling of PD. Schondorf et al. [25]
observed increased levels of a-synuclein and glucosylcer-
amide as well as lysosomal and autophagic defects in
neurons from GBA1 PD-iPSC. Importantly, these patho-
logical phenotypes could be rescued by correction of the
mutations.
Alzheimer’s disease
Alzheimer’s disease (AD) is caused by progressive
degeneration and loss of neurons and synapses throughout
the brain [26]. Most of early-onset familial AD (FAD) can
be attributed to mutations in one of three genes: APP, PS1
and PS2, while many genetic and environmental factors
may co-contribute to determining the sporadic AD (SAD)
[27]. The investigation of AD was extremely limited
until FAD-derived iPSCs with PS1 (A246E) and PS2
(N141I) mutations were established. In FAD-iPSC-derived
differentiated neurons, the secretion of amyloid-beta (Ab)
was significantly increased and sharply responds to c-
secretase modulators and inhibitors [28]. Furthermore,
iPSC-derived neuronal cells showed AD-like biochemical
features, such as an increase in Ab ratio. These neurons
have reduced to secrete Ab when treated with b-secretase
inhibitor, c-secretase inhibitor, and a nonsteroidal antiin-
flammatory drug. During the differentiation stages, how-
ever, there existed different susceptibilities to these drugs
[29]. Other iPSCs model was established from FAD
patients with a duplication of APP gene and two cases of
SAD. Higher level of phospho-tau and glycogen synthase
kinase-3 in lines with elevated Ab represented novel
observations in neurons from one of the SAD cases.
Interestingly, these alterations could be alleviated by b-
secretase, not c-secretase, inhibitor treatment [30]. Doco-
sahexaenoic acid (DHA) may actually be effective for
some patients for the reason that the stress responses in the
AD neural cells were alleviated when treated with DHA,
making possible the iPSC technology for validation and
identification of promising drugs [31].
Huntington’s disease
Huntington’s disease (HD) is a progressive neurodegener-
ative genetic disease associated with a wide variety of
motor impairment and psychiatric symptoms caused by
excessive CAG trinucleotide expansions of Huntingtin
gene (HTT) [32]. The first established human HD-iPSC
model from HD patients carrying 72 CAG repeats was
reported in 2008 [33]. Striatal neurons and HD neural stem
cells produced from iPSCs exhibited elevated caspase
activity after the withdrawal of growth factors which
indicate apoptosis, but no overt cell death phenotype was
reported [34]. Experimental analysis of proteins revealed
amounts of distinct alternations in protein expression in the
HD iPSCs [35]. Jeon et al. converted HD-iPSC into
GABAergic striatal neurons and relavent behavior recov-
ered in a grafted rat after transplantation of HD-iPSC
derived neural precursors. Though showing no overt HD
phenotype, the disease-specific iPSCs sharply responded to
proteasome inhibition and expressed several markers of
HD pathology after transplantation at later time points [36,
37]. Additional HD-phenotypes, including altered mito-
chondrial bioenergetics and susceptibility to cell death
were reported in a subsequent study. These alterations
accompanied with pathogenic HD signaling pathways
could be reversed by the substitution of a normal repeat for
the expanded CAG repeat using homologous recombina-
tion [38]. A more complete study by the HD Consortium
demonstrated hundreds of distinct differences between HD
and wide-type (WT) iPSCs, showing clear signs of HD-
related pathology in several lineages. The lines with the
Neurol Sci (2015) 36:21–27 23
123
longer CAG repeat expansions had more severe patholog-
ical phenotypes and ultimately lead to neuronal death [39].
These findings revealed that HD-iPSCs could be a well-
characterized and unique resource to elucidate disease
mechanisms.
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is the most common
form of progressive motor neuron disorder with varied
etiology characterized by rapidly progressive weakness and
muscle atrophy. This disease strikes people in their 40s,
approximately 20 % of familial ALS cases were linked to
dominant mutations in the SOD1 gene [40]. Other different
genes, including VAPB, TDP-43 and FUS have also been
implicated in ALS [41, 42]. ALS-iPSCs were developed
using skin fibroblasts from two octogenarian sisters with
SOD1 mutations and then converted into spinal motor
neurons, but no assay of ALS relevant phenotype or
compared with neurons from controls were performed in
this study [43]. Another iPSC-derived motor neurons
(MNs) possessing SOD1 mutations developed neurofila-
ment (NF) inclusions. Importantly, conditional expression
of NF-L in these MNs corrected the NF subunit proportion,
mitigating NF aggregation and neurite degeneration [44].
The mutant astrocytes from iPSCs harboring a mutation in
the TDP-43 gene exhibited subcellular mislocalization of
TDP-43, increased levels of TDP-43, and reduced cell
survival. Further co-culture assays showed these astrocytes
did not adversely affect survival of cocultured neurons
[45]. Another TDP-43 iPSC-derived MNs recapitulated the
disease phenotypes, including decreased survival,
increased cellular vulnerability, and elevated levels of
soluble and detergent-resistant TDP-43 protein [46].
Researchers also generated iPSCs from patients which
carry the VAPB mutation as well as from their healthy
siblings. The finding suggested that reduced levels of
VAPB protein in MNs could be involved in the patho-
genesis of ALS8 [47]. Test for chemical compounds on
differentiated MNs showed that the abnormal ALS MNs
phenotype could be rescued by anacardic acid, suggesting
that special MNs may be a new approach for elucidating
ALS disease mechanisms and for screening candidate
drugs [48].
Spinal muscular atrophy
Spinal muscular atrophy (SMA) is an autosomal recessive
genetic disease characterized by the loss of the survival
motor neuron (SMN) [49]. There are two SMN genes in
humans, SMN1 and SMN2, and the loss of the SMN1 gene
primarily caused SMA [50]. To model SMA, scientists
generated iPSCs from a child carrying SMN1 mutation.
These cells manifested clear signs of motor neurons and
differentiated neurons showed the reduction in cells size
and number compared to controls at later stages, indicating
they underwent substantial degeneration. Excitingly, the
administration of valproic acid and tobramycin could
reverse the endogenous SMN protein level in differentiated
neurons and astrocytes [51]. Another established neuronal
cultures rescued the phenotype of delayed neurite out-
growth and restored normal motoneuron differentiation by
overexpressing SMN, accelerating the exploration of the
underlying mechanisms of SMA pathogenesis [52]. MNs
from two type I SMA subject-derived iPSCs showed ele-
vated activation of caspase-8 and-3 and increased Fas
ligand-mediated apoptosis. Moreover, distinct inhibitors of
apoptotic pathways may reduce motor neuron cell death
[53]. Another study has focused on genetic correction for
autologous cell therapy. Uncorrected SMA-iPSCs derived
motor neurons manifested disease-specific features.
Delightfully, these phenotypes were ameliorated in genet-
ically corrected controls, suggesting that genetically cor-
rected special motor neurons could be a source for future
therapeutic strategy [54]. Novel observations of reduced
androgen receptor levels, reduced HDAC6, and repeat
instability provided evidence that SMA-iPSC derived MNs
could be new avenues for further investigation of the dis-
ease mechanism and development of effective therapy [55].
Inherited ataxias
Inherited ataxias may show autosomal dominant, autoso-
mal recessive modes of inheritance. Friedreich ataxia
(FRDA) is an autosomal recessive ataxia, accounting for
one-half of all hereditary ataxias. Spinocerebellar ataxias
(SCAs) are genetically defined autosomal dominantly
inherited disorders characterized by progressive lack of
motor coordination.
FRDA is caused by large guanine-adenine-adenine
(GAA) expansions in FXN gene on chromosome 9q13,
leading to a transcriptional defect of FXN mRNA and
frataxin [56, 57]. GAATTC triplet repeats in FXN intron 1
in FRDA iPSCs not only expanded at a higher rates but
also exhibited repeat instability [58, 59]. The mismatch
repair enzymes MSH2 were much highly expressed in
iPSCs than fibroblasts and neuronal stem cells. Moreover, a
specific pyrrole-imidazole polyamide which displaced
MSH2 in FRDA iPSCs could partially impede repeat
expansion [59]. Studies above demonstrated that GAA
repeats instability might start early during ontogenesis and
the highly active mismatch repair system is related to the
GAATTC triplet repeats. Another iPSCs presented an
instable repeats of GAA expansion, but was failed to find
biochemical phenotypes [60]. Recently, a new develop-
ment-based differentiation protocol was applied to
24 Neurol Sci (2015) 36:21–27
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differentiate FRDA and control iPSCs into peripheral
sensory neurons and neural crest progenitors. Increased
expression of frataxin during sensory specification for
control cells was identified compared to FRDA peripheral
sensory neurons. Whereas, a pronounced deficiency of
frataxin was observed in FRDA iPSCs and neural crest
cells, rather than controls [61].
SCA3, also known as Machado-Joseph disease, is the
most common subtype of SCAs in China, which is caused
by an abnormal CAG trinucleotide repeat expansion in
ATXN3 gene [62]. The formation of sodium dodecyl sulfate
insoluble aggregates was observed in L-glutamate-induced
excitation of iPSC-derived neurons and calpain inhibition
could abolish these pathological changes. However,
inclusion bodies and increased cell death were not
observed, suggesting the excitation-induced protein
aggregation is an early event [63].
Familial dysautonomia
Familial dysautonomia (FD) is a debilitating neurodegen-
erative disease and the most common mutation is in a
splice site of the IKBKAP gene involved in transcriptional
elongation, resulting in reduced levels of IKAP protein
[64]. Researchers differentiated patient-specific FD-iPSCs
into peripheral neurons directly. Tissue-specific mis-splic-
ing of IKBKAP in vitro and low level of normal IKBKAP
transcript expressed in patient neural crest precursors were
observed. The potency treatment of rescuing the mutant
splice combines with improving neuronal differentiation
and migration were also concluded [65, 66]. Later, 6,912
compounds were screened, while 8 hits were characterized
that rescued expression of IKBKAP. SKF-86466, one of 8
hits, not only induced IKBKAP transcription but also res-
cued the expression of IKAP protein and the disease-spe-
cific loss of autonomic neuron sign [67]. Taken together,
small molecule discovery in these newly disease models
can gain novel insights into human disease pathogenesis
and promising treatment.
Potential and challenges
The promising iPSC technology has the potential to model
and treat neurodegenerative diseases. Patient-derived iPSCs
can be rewound to affected neuronal subtypes via in vitro
differentiation or repaired iPS cells using gene targeting to
repair disease-causing mutation. One notable potential is to
apply these affected neuronal subtypes to develop promising
drugs that are most suitable for the patient associated with
their efficacy and toxicity profile. The generation of iPSCs
permits the production of large scale of central nervous
system cell with specific genotype, providing an unlimited
amount of experimental materials. The other potential is to
develop autologous-repaired iPS cells for cell therapy. When
transplanting desired cells into patients, neural function
could be restored and long-term immuno-suppression may
not be necessary. Moreover, transplantation of glial cells,
such as astrocytes that would restore the motor neurons
potentially, can also used for neuroprotection.
However, it is not until this technology ready for clinical
applications that its limitations were overcame. Firstly,
initial method that introduction of factors by retrovirus or
lentivirus might provide the possibility of oncogene reac-
tivation [3, 4]. Apart from safety, the genetic and epigenetic
status of clones might have varied after reprogramming.
Although the non-integrating approaches significantly
reduced the risk of tumorigenesis and epigenetic variation,
researchers need to be cautious and select the stable lin-
eages for differentiation studies. Epigenetic modifications
could be significant in disease manifestation and the erasure
of epigenetic marks during reprogramming is important [7–
13]. Secondly, how to generate disease-relevant phenotype
in vitro is also a challenge. The appearance of disease
phenotype is the most important feature for disease mod-
eling. Current iPSC-models were generated from patients
containing mutations in known gene. However, many
patients, such as PD and ALS, have an unidentified genetic
component that is coupled with environmental factors.
Importantly, the majority of neurodegenerative disorders
are age-dependent and age is considered to be a risk factor
that contributes to the disease development. As current
culture system involved no disease-triggering factors on
disease, the iPSCs might no longer reflect relevant patho-
genesis. Moreover, long-term culture was poorly controlled
and could be compromised by excessive cell death. Thirdly,
protocols for differentiating iPSCs towards different sub-
types of neurons cannot be ignored. Up till now, greater
progress has been made in generating matured populations
of distinct neurons and glia for the purpose of screening
drugs and replacement therapy. However, these cells may
not truly reflect the cellular responses to compounds that the
body would have at a physiological level. Lastly,
researchers still face the problems of low efficiency con-
version and laborious to conduct. The average conversion
efficiency of each methods mentioned above is less than
1 %, which further restrict the extensively use of the tech-
nology [1]. Efficiency needs to be improved if these pro-
tocols apply for high-throughout drug screening.
Conclusions
Taken together, iPSC technology for modeling of neuro-
degenerative diseases has both benefits and limitations.
Patient-derived cells open new avenues to investigate the
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neurodegenerative diseases development and remarkably
easily could usher in new therapies and cloning techniques.
Many hurdles must be overcome before new clinical
therapies based on these cells. This will help ensure safety
and eventually beneficial to human beings.
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